We study neurodegeneration and dementia in ALS, FTD and AD to find novel therapeutic applications and biomarkers of vascular injury.
We look how blood-brain barrier dysfunction and vascular remodeling leads to increased severity of stroke, Amyotrophic Lateral Sclerosis (ALS) and FTD using bioinformatics, in-vivo rodent models and clinical samples. We collaborate with the leading neurology centers in Europe and US including UZ Leuven in Belgium, Univ. Utrecht in Holland, Ulm Univ. in Germany and UCSD in San Diego. Our results lead to novel off-label drug applications to therapy and biomarkers in neurodegeneration including ALS, stroke and Multiple Sclerosis.
Methods: Single cell transcriptome analysis, Cell-type specific expression enrichment, Expression network analysis, Histology, Immunostainings, Immunobead plasma proteomics.
Collaborations with clinical and research groups:
- VIB-KU Leuven Center for Brain & Disease Research, Belgium. Prof. Philip van Damme
- UMC Utrecht Brain Center, Netherlands. Prof. Jan Veldink
- Neurology Dept. University Ulm, Germany. Prof. Albert Ludolph
- Neurosciences Dept. University of California, San Diego, US. Prof. John Ravits
- SciLifeLab, School of Biotechnology, KTH, Sweden. Prof. Peter Nilsson
- Neurosciences Dept. Karolinska Institute., Sweden. Prof. Eva Hedlund
Our 2014 ALS Ice Bucket Challenge:
Blood-brain barrier dysfunction in ALS
In the News: